基础医学院院长论坛(Daniel Figeys, Ph.D.)

报告题目: The microbiome in inflammatory bowel disease and microbiome-drug interactions

报 告 人: Daniel Figeys, Ph.D.

Professor, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa

时间: 2019年10月29日(星期二)下午15:00

地点: 卫生楼二层中厅

主 持 人: 刘小云 研究员

报告简介:

222.jpg

Changes in the gut microbiome have been implicated in the pathogenesis of many diseases. In the first part of the presentation, I will discuss the interaction between the microbiome and the gut in inflammatory bowel disease (IBD). We are interested in the functional changes in the microbiome and the host that accompany the onset of the disease and whether these changes are potentially involved in the disease. In order to assess the changes in the microbiome and host-microbiome interactions, we collected mucosal-luminal interface samples and biopsies from a pediatric IBD inception cohort. These samples are used to characterize the human and microbiome proteomes and their regulations through post-translational modifications (PTM).

Eventhough omic approaches can be used to study dysbiosis, our abiltiy to intervene to correct the dysbiosis is limited. This is primarily due the lack of tools for screening compounds against microbiome. Currently, compounds are either screened against individual bacteria or using animal models. In the second part of the presentation, we will discuss the development of a rapid assay for individual’s microbiome (called RapidAIM). RapidAIM is an ex vivo assays to study the effects of drugs on the human gut microbiome. In this assay, series of compounds can be screen against a panel of individual microbiomes allowing the characterisation of the microbiome responses and the pathways activated by the compounds.

Selected Publications:

1. Starr, A. E. et al. Proteomic and Metaproteomic Approaches to Understand Host-Microbe Interactions. Anal Chem. 2018, 90(1): 86-109. doi: 10.1021/acs.analchem.7b04340

2. Starr, A. E. et al. Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC. Gut. 2017, 66(9): 1573-1583. doi: 10.1136/gutjnl-2015-310705

3. Mottawea, W. et al. Altered intestinal microbiota-host mitochondria crosstalk in new onset Crohn's disease. Nat Commun. 2016, 7:13419. doi: 10.1038/ncomms13419

4. Zhang, X. et al. Deep Metaproteomics Approach for the Study of Human Microbiomes. Anal Chem. 2017, 89(17): 9407-9415. doi: 10.1021/acs.analchem.7b02224

欢迎师生参加!

最新打鱼棋牌游戏 佳永配资配资门户 能胜配资 快乐8开奖查询 北京十一选五走势一 哪个网站可以青海十一选五 幸运赛车开奖官网 上海 股指配资 推荐 广西快乐十分规则 内蒙古快3开奖l结 广西11选5手机版走势图 内蒙古快3形态走势图彩经网 陕西11选5怎么下载 天津时时彩二星走势图 加拿大快乐8的算法 澳洲幸运5几点开始 互利计划